S-1: Aptevo Therapeutics Files S-1 for $25 Million Equity Raise Amidst Dilution Concerns

Aptevo Therapeutics Inc. has filed an S-1 registration statement to allow a selling stockholder to resell up to 8.25 million shares, enabling the company to potentially raise up to $25 million through a Standby Equity Purchase Agreement to fund its clinical-stage oncology pipeline.

Summary

• Aptevo Therapeutics Inc. (APVO) has filed an S-1 registration statement for the resale of up to 8,250,825 shares of common stock by YA II PN, LTD., a selling stockholder.
• The company will not receive proceeds from the selling stockholder's resale of shares under this prospectus.
• Aptevo may receive up to $25.0 million in aggregate gross proceeds from its own sales of common stock to YA II PN, LTD. under a Standby Equity Purchase Agreement (Purchase Agreement) dated June 16, 2025.
• These sales to YA would occur from time to time over 36 months, at a price equal to 96% of the lowest of three daily volume weighted average prices (VWAPs) during a pricing period.
• As of June 30, 2025, 3,224,156 shares of common stock were outstanding; the 8,250,825 shares offered by YA represent approximately 72% of the total outstanding shares if fully issued.
• Stockholders approved the issuance and sale of shares to YA in excess of the 19.99% Exchange Cap on July 24, 2025, removing this limitation.
• The company paid a $25,000 structuring fee and will pay a 2.00% commitment fee (of the $25.0 million) to YA in five equal quarterly installments.
• Aptevo is a clinical-stage biotechnology company focused on novel bispecific immunotherapy candidates for cancer, utilizing its ADAPTIR and ADAPTIR-FLEX platform technologies.
• Clinical candidates include mipletamig (CD3xCD123 T cell engager) in Phase 1b/2 RAINIER trial for frontline acute myelogenous leukemia (AML) initiated August 2024, and ALG.APV-527 (4-1BB and 5T4 targeter) for solid tumor types.
• Preclinical candidates include APVO455 (Nectin-4 x CD3 bispecific T-cell engager), APVO603, APVO711, and APVO442.
• The company effected a 1-for-20 reverse stock split on May 23, 2025, with shares trading on a split-adjusted basis from May 27, 2025.
• Aptevo regained compliance with Nasdaq's minimum shareholders' equity requirement ($2.5 million) as of July 1, 2025, after raising approximately $15.9 million in additional equity capital during the quarter ended June 30, 2025.
• Net loss for the year ended December 31, 2024, was $(24,130) thousand, with a basic and diluted net loss per share of $(1,747.79) (post-split adjusted).
• Net loss for the three months ended March 31, 2025, was $(6,408) thousand, with a basic and diluted net loss per share of $(87.87) (post-split adjusted).
• The company has 12,585,033 common warrants outstanding from prior offerings, which could yield up to an additional $46.9 million in gross proceeds if exercised.

Sentiment

Score: 4

Explanation: The filing indicates a necessary step for a clinical-stage biotech to secure future funding, which is positive for continued operations and pipeline development. However, it highlights significant potential dilution for existing shareholders, ongoing substantial financial losses, and past Nasdaq compliance issues, reflecting a high-risk investment profile.

Positives

• Secured a Standby Equity Purchase Agreement with YA II PN, LTD. for up to $25.0 million, providing a potential source of future capital.
• Stockholders approved the issuance of shares to YA in excess of the Exchange Cap, removing a significant limitation on potential capital raises through this agreement.
• Regained compliance with Nasdaq's minimum shareholders' equity requirement by raising approximately $15.9 million in Q2 2025, preventing potential delisting.
• Advancing a pipeline of novel bispecific immunotherapy candidates for cancer, including two clinical-stage assets (mipletamig and ALG.APV-527) and four preclinical candidates.
• Proprietary ADAPTIR and ADAPTIR-FLEX platform technologies offer flexibility in designing immunotherapeutic candidates.

Negatives

• The potential issuance of up to 8,250,825 shares to YA II PN, LTD. represents significant potential dilution, approximately 72% of current outstanding shares, which could adversely affect existing stockholders' economic and voting interests.
• The company will not receive any proceeds from the resale of shares by the selling stockholder under this prospectus, meaning the immediate capital infusion is not direct.
• The actual amount of proceeds the company may receive from sales to YA is uncertain and depends on market conditions and the company's discretion, potentially being less than the $25.0 million commitment.
• Ongoing net losses: $(24,130) thousand for 2024 and $(6,408) thousand for Q1 2025, indicating continued cash burn.
• The company's common stock was recently at risk of Nasdaq delisting due to non-compliance with minimum shareholders' equity, highlighting financial fragility.
• The 1-for-20 reverse stock split was implemented to maintain Nasdaq listing compliance, often a sign of a struggling stock price.

Risks

• Inability to predict the actual number of shares sold under the Purchase Agreement or the gross proceeds received.
• Limitations in the Purchase Agreement, including the Ownership Limitation, could prevent the company from raising the full Commitment Amount.
• Need to file additional registration statements if more than 8,250,825 shares are sold to YA, incurring further costs and delays.
• Substantial dilution to existing stockholders from the issuance and sale of shares to YA.
• Resale of a significant amount of shares by YA could cause the market price of common stock to decline and become highly volatile.
• Broad discretion in the use of net proceeds from the Purchase Agreement, with no guarantee of effective application.
• Investors who buy shares at different times will likely pay different prices, leading to varying dilution and investment outcomes.
• Future sales and issuances of common stock or other securities could result in significant dilution and cause the share price to decline.
• Risk of short selling strategies driving down the market price of common stock.
• Risk of delisting from the Nasdaq Capital Market if compliance with listing requirements (e.g., minimum bid price of $1.00, minimum shareholders' equity of $2.5 million) is not maintained.
• If delisted and trading below $5.00 with net tangible assets of $6,000,000 or less, the stock will be subject to 'penny stock' rules, making transactions difficult and adversely affecting trading activity.
• The company's ability to continue as a going concern is a risk factor.
• Failure to obtain regulatory approval for current and future drug candidates.
• Inability to secure sufficient funding and alternative sources of funding to support business objectives, product development, and commercialization efforts.
• The success of clinical development activities, clinical trials, and research and development programs is uncertain.
• Ability to retain key employees, consultants, and advisors.
• Ability to obtain, maintain, protect, and enforce sufficient intellectual property rights for candidates and technology.
• Impact of legislative, regulatory, or policy changes.
• Adverse impact from macroeconomic conditions, including inflation, cost of capital, and changes in economic policies and regulations.

Future Outlook

The company intends to use any net proceeds from sales of shares under the Purchase Agreement for working capital, funding clinical programs, advancing new programs, business development activities, and general corporate purposes. The actual amount and timing of proceeds will vary based on factors including the number of shares sold and market prices. The company's ability to continue as a going concern and maintain Nasdaq listing compliance are critical for its future operations and funding.

Industry Context

Aptevo Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on oncology and immunotherapy. The development of novel bispecific immunotherapy candidates, such as T-cell engagers, aligns with a significant trend in cancer treatment aiming for more targeted and effective therapies. The reliance on dilutive equity financing, as evidenced by this S-1 filing and prior capital raises, is common for clinical-stage biotech companies that do not yet have commercialized products generating substantial revenue. Maintaining Nasdaq listing is crucial for access to public capital markets, a common challenge for smaller biotech firms with ongoing losses.

Comparison to Industry Standards

• The use of a Standby Equity Purchase Agreement (SEPA) with an institutional investor like YA II PN, LTD. is a common financing mechanism for small-cap biotechnology companies, similar to agreements seen with other firms in the clinical-stage oncology space that require flexible access to capital without traditional underwritten offerings.
• The significant potential dilution (72% of outstanding shares) from the registered resale is high, even for a biotech company, and would be considered substantial compared to typical equity raises by more mature companies or those with late-stage assets.
• The 1-for-20 reverse stock split and prior Nasdaq non-compliance issues regarding minimum shareholders' equity and bid price are indicative of financial distress and challenges in maintaining market valuation, a situation often faced by smaller, unprofitable biotech companies, contrasting with more stable, revenue-generating pharmaceutical or biotech firms.

Corporate Governance

Related Party Transactions

• The Standby Equity Purchase Agreement with YA II PN, LTD. is a significant financial arrangement. YA II PN, LTD. is the selling stockholder in this registration, and the company pays them a structuring fee ($25,000) and a commitment fee (2.00% of $25.0 million).

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from future share issuances under the Purchase Agreement, which could reduce the value of their holdings. However, the capital raise provides funding for continued operations and pipeline development, which is essential for long-term value creation.
• **Employees**: Continued funding supports ongoing research and development activities, potentially ensuring job security and progress on clinical programs.
• **Creditors**: The capital raise improves the company's liquidity and financial position, potentially reducing credit risk.
• **Patients/Healthcare Community**: Continued funding supports the development of novel cancer immunotherapies, potentially leading to new treatment options.

Next Steps

• The company may, at its discretion, direct YA II PN, LTD. to purchase shares under the Standby Equity Purchase Agreement from time to time.
• Proceeds from sales to YA will be used for continued development of pipeline products, advancement of new programs, business development activities, and general corporate purposes.
• The RAINIER trial (Phase 1b/2 for mipletamig) is ongoing, having been initiated in August 2024.
• The company must continue to maintain compliance with Nasdaq's listing requirements to avoid delisting.

Key Dates

Recommendation

The filing outlines a critical financing mechanism for Aptevo Therapeutics, a clinical-stage biotech company with a pipeline of novel cancer immunotherapies. While the potential for up to $25 million in capital from the Standby Equity Purchase Agreement is vital for funding ongoing R&D and maintaining operations, the significant potential dilution (up to 72% of current outstanding shares) presents a substantial risk to existing shareholders. The company's history of net losses and recent Nasdaq compliance issues underscore its high-risk profile. For a seasoned investor, the 'hold' recommendation acknowledges the necessity of this capital raise for the company's survival and continued development of its promising, albeit early-stage, pipeline. However, it also implicitly advises against new speculative 'buy' positions given the inherent risks, including further dilution, market volatility, and the long, uncertain path to commercialization for biotech assets. Existing investors should 'hold' if they maintain conviction in the long-term potential of the pipeline despite the near-term dilutive effects.

Keywords

Biotechnology, Oncology, Immunotherapy, Bispecific Antibodies, T-cell Engagers, SEC Filing, S-1 Registration, Equity Offering, Dilution, Capital Raise, Nasdaq Listing, Clinical Trials, Drug Development, AML, Solid Tumors, Reverse Stock Split